Class A
ISIN: LU1491986011
CATEGORY: Sector Equity Biotechnology
KEY INFORMATIONat 01.12.2021
Net Asset Value187,24 EUR
Fund Size (mln)17.729.102 EUR
Launch Date 2 ott 2012
BenchmarkBENCHMARK COMPOSITE 17389
MANAGEMENT INFORMATION
SicavPHARUS SICAV
Management CompanyPHARUS MANAGEMENT LUX SA
Investment ManagerPharus Asset Management SA
DOCUMENTS
N.A.
RISK & REWARD PROFILE
Lower Risk
Highest Risk
Potentially lower return
Potentially higher return
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
INVESTMENT OBJECTIVE
The sub-fund aims to achieve growth by investing in equities or similar securities issued by biopharmaceutical companies that are at the forefront of innovation in the medical sector. The sub-fund will invest at least two-thirds of its total assets in equities issued by companies operating in this sector.
MANAGER COMMENT
The fund recorded a negative performance of -0.96% in October.
The fund invests in companies in the pharmaceutical, medical and biotechnology sectors, with a particular interest in the latest technological and scientific innovations.
Specifically, the fund focuses on small and mid-cap companies, pursuing high diversification with a portfolio of over 150 names. At the geographic allocation level, we remain focused on the US market, while maintaining full hedging against the EUR / USD exchange rate.
We believe that the fund represents an attractive investment opportunity in a sector that will prove to be one of the key drivers of the coming years and which is suffering from a clear YTD underperformance compared to all major equity indices.
The main reason for this underperformance lies in the uncertainty of the Biden government's plan to extend and expand healthcare spending.
PERFORMANCE
Last updated on 01.12.2021
ASSET ALLOCATION
*
No coverage or derivatives are included
CURRENCY ALLOCATION
*
No coverage or derivatives are included
COUNTRY ALLOCATION
TOP TEN HOLDING
Chemocentryx Inc 1.98 %
Seres Therapeutics Inc 1.47 %
Dicerna Pharmaceuticals Inc 1.44 %
Cytokinetics Inc 1.13 %
Ligand Pharmaceuticals 1.01 %
Arcus Biosciences Inc 0.98 %
Avid Bioservices Inc 0.96 %
Fibrogen Inc 0.94 %
Apellis Pharmaceuticals Inc 0.94 %
Acadia Pharmaceuticals Inc 0.93 %
SECTOR ALLOCATION
Current risk profile selected: